Glucosamine sulfate for knee osteoarthritis: Science and evidence-based use

Therapy

Volumn 7, Issue 6, 2010, Pages 591-604

  Roman Blas, Jorge A ^a   Castaeda, Santos ^a   Largo, Raquel ^a   Herrero Beaumont, Gabriel ^a  

^a HOSPITAL UNIVERSITARIO FUNDACIÓN JIMÉNEZ DÍAZ   (Spain)

Author keywords

clinical trials; disease modification; glucosamine sulfate; IL 1; joint space narrowing; osteoarthritis; pharmacokinetics; safety; structure modification; symptom modification

Indexed keywords

CELECOXIB; CHONDROITIN SULFATE; CYCLOOXYGENASE 2; GLUCOSAMINE; GLUCOSAMINE SULFATE; INTERLEUKIN 1BETA; PARACETAMOL; PLACEBO;

ABDOMINAL PAIN; CLINICAL TRIAL; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DIABETES MELLITUS; DIARRHEA; DROWSINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG FORMULATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG SYNOVIAL FLUID LEVEL; DYSPEPSIA; FATIGUE; GLUCOSE BLOOD LEVEL; HEMATOLOGICAL PARAMETERS; HUMAN; INSULIN BLOOD LEVEL; KNEE OSTEOARTHRITIS; MAXIMUM PLASMA CONCENTRATION; METABOLIC PARAMETERS; NAUSEA; NONHUMAN; PHARMACODYNAMICS; POSTMARKETING SURVEILLANCE; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; TISSUE DISTRIBUTION; VERTIGO;

EID: 78649342425     PISSN: 14750708     EISSN: 1744831X     Source Type: Journal    
DOI: 10.2217/thy.10.67     Document Type: Review

References (71)

1. Felson DT, Lawrence RC, Dieppe PA et al. Osteoarthritis: new insights. Part 1: the disease and its risk factors. Ann. Intern. Med. 133,635-646 (2000).
2. Felson DT, Zhang Y: An update on the epidemiology of knee and hip osteoarthritis with a view to prevention. Arthritis Rheum. 41, 1343-1355 (1998).
3. Oliveira SA, Felson DT, Reed JI, Cirillo PA, Walker AM: Incidence of symptomatic hand, hip and knee osteoarthritis among patients in a health maintenance organisation. Arthritis Rheum. 38, 1134-1141 (1995).
4. Guccione AA, Felson DT, Anderson JJ et al.: The effects of specific medical conditions on the functional limitations of elders in the Framingham Study. Am. J. Public Health 84, 351-358(1994)
5. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. Arthritis Rheum. 43, 1905-1915 (2000).
6. Jordan KM,Arden NK, Doherty M et al. EULAR recommendations 2003, an evidence based approach to the management of knee osteoarthritis: report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials {ESCISIT). Ann. Rheum. Dis. 62, 1145-1155 (2003).
7. Zhang W, Doherty M, Arden N et al.: EULAR evidence based recommendations for the management of hip osteoarthritis: report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann. Rheum. Dis. 64, 669-681 (2005).
8. Zhang W, Moskowitz RW, Nuki G et al.: OARSI recommendations for the management of hip and knee osteoarthritis, Part I: critical appraisal of existing treatment guidelines and systematic review of current research evidence. Osteoarthr. Cartil. 15,981-1000 (2007).
9. Zhang W, Moskowitz RW, Nuki G et al: OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthr. Cartil. 16, 137-162 (2008).
10. Zhang W, Nuki G, Moskowitz RW et al.: OARSI recommendations for the management of hip and knee osteoarthritis, part III: changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthr. Cartil. 18,476-499 (2010).
11. Setnikar I, Cereda R, Pacini MA, Revel L: Antireactive properties of glucosamine sulfate. Arzneimittelforschung 41, 157-161 (1991).
12. Reginster JY, Bruyere O, Neuprez A: Current role of glucosamine in the treatment of osteoarthritis. Rheumatology (Oxford) 46,731-735 (2007).
13. Towheed T, Maxwell L, Anastassiades TP et al. Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst. Rev. 2, CD002946 (2009).
14. Noyszewski EA, Wroblewski K, Dodge GR et al.: Preferential incorporation of glucosamine into the galactosamine moieties of chondrokin sulfate in articular cartilage explants. Arthritis Rheum. 44, 1089-1095 (2001).
15. Bassleer C, Rovati LC, Franchimont P: Glucosamine sulfate stimulates proteoglycan production in human chondrocytes in vitro. Osteoarthr. Cartil. 6, 427-434 (1998).
16. Piperno M, Reboul P, Helio Le Graverand MP et al.: Glucosamine sulfate modulates dysregulated activities of human osteoarthrkic chondrocytes in vitro. Osteoarthr. Cartil. 8, 207-212 (2000).
17. Dodge GR, Jimenez SA: Glucosamine sulfate modulates the levels of aggrecan and matrix metalloproteinase-3 synthesized by cultured human osteoarthritis articular chondrocytes. Osteoarthr. Cartil. 11,424-432 (2003).
18. Sandy JD, Gamett D, Thompson V, Verscharen C: Chondrocyte-mediated catabolism of aggrecan: aggreganase-dependent cleavage induced by interleukin-1 or retinoic acid can be inhibited by glucosamine. Biochem. J. 335, 59-66 (1998).
19. Altman RD, Cheung H: Glucosamine sulfate on cartilage: lapine study. Arthritis Rheum. 44(Suppl. 9), 1535 (2001).
20. Tiraloche G, Girard C, Chouinard L et al.: Effect of oral glucosamine on cartilage degradation in a rabbit model of osteoarthritis. Arthritis Rheum. 52, 1118-1128 (2005).
21. Mroz PJ, Silbert JE: Use of 3H-glucosamine and 35S-sulfate with cultured human chondrocytes to determine the effect of glucosamine concentration on formation of chondrokin sulfate. Arthritis Rheum. 50, 3574-3579(2004).
22. Biggee BA, Blinn CM, McAlindon TE, Nuke M, Silbert JE: Low levels of human serum glucosamine after ingestion of glucosamine sulfate relative to capability for peripheral effectiveness. Ann. Rheum. Dis. 65,222-226 (2006).
23. Setnikar I, Rovati LC: Absorption, distribution, metabolism and excretion of glucosamine sulfate: a review. Arzneimittelforschung51, 699-725 (2001).
24. Laverty S, Sandy JD, Celeste C et al.: Synovial fluid levels and serum pharmacokinetics in a large animal model following treatment with oral glucosamine at clinically relevant doses. Arthritis Rheum. 52, 181-191 (2005).
25. Varghese S, Theprungsirikul P, Sahani S, Hwang N, Yarema KJ, Elisseeff JH: Glucosamine modulates chondrocyte proliferation, matrix synthesis, and gene expression. Osteoarthr. Cartil. 15, 59-68 (2007).
26. Gouze JN, Bordji K, Gulberti S et al.: Interleukin-lp down-regulates the expression of glucuronosyltransferase I, a key enzyme priming glycosaminoglycan biosynthesis: influence of glucosamine on interleukin-lp-mediated effects in rat chondrocytes. Arthritis Rheum. 44, 351-360 (2001).
27. Shikhman AR, Kuhn K, Alaaeddine N, Lotz M: N-acetylglucosamine prevents IL-lβ-mediated activation of human chondrocytes. J. Immunol. 166, 5155-5160 (2001).
28. Gouze JN, Bianchi A, Becuwe P et al.: Glucosamine modulates IL-1-induced activation of rat chondrocytes at a receptor level, and by inhibiting the NF-κB pathway. FEBSLett. 510, 166-170 (2002).
29. Largo R, Alvarez-Soria MA, Dlez-Ortego I et al.: Glucosamine inhibits IL-lβ-induced NFKB activation in human osteoarthrkic chondrocytes. Osteoarthr. Cartil. 11,290-298 (2003).
30. Alvarez-Soria MA, Largo R, Calvo E, Egido J, Herrero-Beaumont G: Differential anticatabolic profile of glucosamine sulfate versus other anti-osteoarthrkic drugs on human osteoarthrkic chondrocytes and synovial fibroblast in culture. Osteoarthr. Cartil. 13(Suppl. A), P309 (2005).
31. Piepoli T, Zanelli T, Letari O et al.: Glucosamine sulfate inhibits IL-1-stimulated gene expression at concentrations found in humans after oral intake. Arthritis Rheum. 52(Suppl. 9), 1326 (2005).
32. Ukterlinden EJ, Jahr H, Koevoet JLM et al.: Glucosamine decreases expression of anabolic and catabolic genes in human osteoarthrkic cartilage explants. Osteoarthr. Cartil. 14, 250-257 (2006).
33. Hoffer LJ, Kaplan LN, Hamadeh MJ, Grigoriu AC, Baron M: Sulfate could mediate the therapeutic effect of glucosamine sulfate. Metabolism 50, 767-770 (2001).
34. Cordoba F, Nimni ME: Chondrokin sulfate and other sulfate containing chondroprotective agents may exhibit their effects by overcoming a deficiency of sulfur amino acids. Osteoarthr. Cartil. 11, 228-230 (2003).
35. Altman RD: Glucosamine therapy for knee osteoarthritis: pharmacokinetic considerations. Expert Rev. Clin. Pharmacol. 2,359-371 (2009)
36. Persian S, Roda E, Rovati LC et al.: Glucosamine oral bioavailability and plasma pharmacokinetics after increasing doses of crystalline glucosamine sulfate in man. Osteoarthr. Cartil. 13, 1041-1049 (2005).
37. Roda A, Sabatini L, Barbieri A et al.: Development and validation of a sensitive HPLC-ESI-MS/MS method for the direct determination of glucosamine in human plasma. J. Chromatogr. 844, 119-126 (2006)
38. Persian S, Locatelli M, Fiorentino S, Rovati LC, Roda A: Absolute bioavailability of glucosamine after administration of crystalline glucosamine sulfate in rats. Osteoarthr. Cartil. 13(Suppl. A), P161 (2005)
39. Persian S, Rotini R, Trisolino G et al.: Glucosamine plasma and synovial fluid concentrations before and after oral administration of crystalline glucosamine sulfate in knee osteoarthritis patients. Arthritis Rheum. 52(Suppl. 9), 1342 (2005).
40. Jackson CG, Plaas AH, Sandy JD et al. The human pharmacokinetics of oral ingestion of glucosamine and chondrokin sulfate taken separately or in combination. Osteoarthr. Cartil. 18, 297-302 (2010)
41. Persian S, Rovati LC, Pastorini E et al. Pharmacokinetics of glucosamine in man after oral administration of crystalline glucosamine sulfate or glucosamine hydrochloride alone or in combination with chondrokin sulfate. Osteoarthr. Cartil, 15(Suppl. C),C223 (2007).
42. Meulyzer M, Vachon P, Beaudry F et al. Comparison of pharmacokinetics of glucosamine and synovial fluid levels following administration of glucosamine sulphate or glucosamine hydrochloride. Osteoarthr. Cartil. 16, 973-979 (2008).
43. McAlindon TE, La Valley MP, Gulin JP, Felson DT: Glucosamine and chondrokin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. JAMA 283, 1469-1475 (2000).
44. Richy F, Bruyere O, Ethgen O et al. Structural and symptomatic efficacy of glucosamine and chondrokin in knee osteoarthritis. A comprehensive metaanalysis. Arch. Int. Med. 163, 1514-1522 (2003).
45. Vlad SC, LaValley MP, McAlindon TE, Felson DT: Glucosamine for pain in osteoarthritis. Arthritis Rheum. 56, 2267-2277 (2007).
46. Reginster JY: The efficacy of glucosamine sulfate in osteoarthritis: financial and nonfinancial conflict of interest. Arthritis Rheum. 56, 2105-2110 (2007).
47. Reginster JY, Deroisy R, Rovati LC et al. Long-term effects of glucosamine sulfate on osteoarthritis progression: a randomized, placebo-controlled clinical trial. Lancet 357, 251-256 (2001).
48. Pavelka K, Gatterova J, Olejarova M et al. Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study. Arch. Intern. Med. 162, 2113-2123 (2002).
49. Bruyere O, Pavelka K, Rovati LC et al. Glucosamine sulfate reduces osteoarthritis progression in postmenopausal women with knee osteoarthritis: evidence from two 3-year studies. Menopause 11, 138-143 (2004).
50. Brandt KD, Mazzuca SA, Conrozier T et al. Which is the best radiographic protocol for a clinical trial of a structure modifying drug in patients with knee osteoarthritis? J. Rheumatol. 29, 1308-1320 (2002).
51. Pavelka K, Bruyere O, Rovati LC et al.: Relief in mild-to-moderate pain is not aconfounder in joint space narrowing assessment of full extension knee radiographs in recent osteoarthritis structure-modifying drug trials. Osteoarthr. Cartil. 11,730-737(2003).
52. McAlindon T: Glucosamine for osteoarthritis: dawn of a new era? Lancet 357, 247-248 (2001).
53. Bruyere O, Pavelka K, Rovati LC et al.: Total joint replacement after glucosamine sulfate treatment in knee osteoarthritis: results of a mean 8-year observation of patients from two previous 3-year, randomised, placebo-controlled trials. Osteoarthr. Cartil. 16, 254-260 (2008).
54. Altman RD, Abadie E, Avouac B et al.: Total joint replacement of hip or knee as an outcome measure for structure modifying trials in osteoarthritis. Osteoarthr. Cartil. 13, 13-19 (2005).
55. Herrero-Beaumont G, Ivorra JA, Del Carmen Trabado MC et al.: Glucosamine sulfate in the treatment of knee osteoarthritis symptoms: a randomised, double-blind, placebo-controlled study using acetaminophen as a side comparator. Arthritis Rheum. 56, 555-567 (2007).
56. Bjordal JM, Ljunggren AE, Klovning A, Slordal L: Non-steroidal anti-inflammatory drugs, including cyclo-oxygenase-2 inhibitors, in osteoarthritis knee pain: meta-analysis of randomised placebo controlled trials. BMJ 329, 1317-1322 (2004).
57. Clegg DO, Reda DJ, Harris CL et al.: Glucosamine, chondrokin sulfate, and the two in combination for painful knee osteoarthritis. N. Engl. J. Med. 358, 795-808 (2006)
58. Various authors: Glucosamine and chondrokin sulfate for knee osteoarthritis. N. Engl. J. Med. 354,2184-2185 (2006).
59. Houpt JB, McMillan R, Wein C, Paget-Dellio SD: Effect of glucosamine hydrochloride in the treatment of pain of osteoarthritis of the knee. J. Rheumatol. 26, 2423-2430 (1999).
60. Hochberg MC: Nutritional supplements for knee osteoarthritis-still no resolution. N. Engl. J. Med. 354, 858-860 (2006).
61. Sawitzke AD, Shi H, Finco MF et al.: The effect of glucosamine and/or chondrokin sulfate on the progression of knee osteoarthritis. Arthritis Rheum. 58, 3183-3191 (2008).
62. Sawitzke AD, Shi H, Finco MF et al.: Clinical efficacy and safety of glucosamine, chondrokin sulfate, their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: 2-year results from GAIT. Ann. Rheum. Dis. 69, 1459-1464 (2010).
63. Scholtissen S, Bruyere O, Neuprez A et al.: Glucosamine sulfate in the treatment of knee osteoarthritis: cost-effectiveness comparison with paracetamol. Int. J. Clin. Pract. 64, 756-762 (2010).
64. Baron AD, Zhu JS, Zhu JH et al.: Glucosamine induces insulin resistance in vivo by affecting GLUT 4 translocation in skelet al muscle. Implications for glucose toxicity. J. Clin. Invest. 96, 2792-2801 (1995).
65. Monauni T, Zenti MG, Cretti A et al.: Effects of glucosamine infusion on insulin secretion and insulin action in humans. Diabetes 49, 926-935 (2000).
66. Pouwels MJ, Jacobs JR, Span PN et al.: Short-term glucosamine infusion does not affect insulin sensitivity in humans. J. Clin. Endocrinol. Metab. 86, 2099-2103 (2001).
67. Tannis AJ, Barban J, Conquer JA: Effect of glucosamine supplementation on fasting and non-fasting plasma glucose and serum insulin concentrations in healthy individuals. Osteoarthr. Cartil. 12,506-511 (2004).
68. Scroggie DA, Albright A, Harris M: The effect of glucosamine-chondrokin supplementation on glycosylated hemoglobin levels in patients wkh Type 2 diabetes mellkus. A placebo-controlled, double-blinded, randomized clinical trial. Arch. Int. Med. 163, 1587-1590 (2003).
69. Rovati LC, Annefeld M, Giacovelli G, Schmid K, Setnikar I: Glucosamine in osteoarthritis. Lancet354, 1640 (1999).
70. Anderson JW, Nicolosi RJ, Borzelleca JF: Glucosamine effects in humans: a review of effects on glucose metabolism, side effects, safety considerations and efficacy. Food Chem. Toxicol. 43, 187-201 (2005).
71. Russell AS, Aghazadeh-Habashi A, Jamali F: Active ingredient consistency of commercially available glucosamine sulfate products. J. Rheumatol. 29, 2407-2409 (2002).